nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

01.03.2010 | Original Article

Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines

verfasst von: F. J. Drummond, A.-E. Carsin, L. Sharp, H. Comber

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Prostate specific antigen (PSA) testing is associated with increased prostate cancer (PCa) incidence. Ireland has no national guidelines on PCa screening and had the highest PCa incidence in Europe, 2006.

Aims

To investigate trends in PSA testing in Ireland.

Methods

Data on PSA tests, 1994–2005, was collated.

Results

Age-standardised rates of PSA testing increased 39 and 25% annually in men <50 and ≥50 years, respectively. Most tests were performed in men 50–69 years; 26 and 22% were performed in men <50 and ≥70 years, respectively. Baseline PSA tests peaked in 2004, at 16% of men. 83% of baseline tests were <4.0 ng/ml. Repeat testing increased with age and PSA level (P < 0.001); men <50 years and with levels <4.0 ng/ml had >1 tests in <21 months. PCa incidence increased 9% annually, 1994–2005.

Conclusions

Uptake of PSA testing was rapid: increased use was simultaneous with increased PCa incidence. National guidelines are needed to manage this important public health issue.

McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD (2004) Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 119(2):174–186PubMed

Mistry K, Cable G (2003) Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 16(2):95–101. doi:10.3122/jabfm.16.2.95 CrossRefPubMed

Pashayan N, Powles J, Brown C, Duffy SW (2006) Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. Br J Cancer 95(3):401–405. doi:10.1038/sj.bjc.6603246 CrossRefPubMed

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13):981–990PubMed

Ilic D, O’Connor D, Green S, Wilt T (2006) Screening for prostate cancer. Cochrane Database Syst Rev 3:CD00472

Andriole GL, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, Crawford ED, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319. doi:10.1056/NEJMoa0810696 CrossRefPubMed

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328. doi:10.1056/NEJMoa0810084 CrossRefPubMed

Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592. doi:10.1093/annonc/mdl498 CrossRefPubMed

Comber H Trends in Irish cancer incidence 1994-2002 with projections to 2020. http://www.ncri.ie/pubs/pubfiles/proj_2020.pdf

10.

A Strategy for Cancer Control in Ireland National Cancer Forum, 2006. http://www.dohc.ie/publications/

11.

Drummond F, Sharp L, Comber H (2008) Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007. IJMS Ir J Med Sci 177(4):317–323. doi:10.1007/s11845-008-0216-1 CrossRef

12.

NCR National Cancer Registry (2001) Cancer in Ireland, 1994 to 1998: incidence, mortality, treatment and survival, report of the National Cancer Registry. Cork, Ireland

13.

Roobol MJ, Roobol DW, Schröder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? Urology 65:343–346. doi:10.1016/j.urology.2004.09.046 CrossRefPubMed

14.

Sirovich BE, Schwartz LM, Woloshin S (2003) Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 289:1414–1420. doi:10.1001/jama.289.11.1414 CrossRefPubMed

15.

Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O’Reilly D, Keane PF, Murray LJ (2004) Evidence of prostate cancer screening in a UK region. BJU Int 93:730–734. doi:10.1111/j.1464-410X.2003.04716.x CrossRefPubMed

16.

Melia J, Moss S (2001) Survey of the rate of PSA testing in general practice. Br J Cancer 85(5):656–657. doi:10.1054/bjoc.2001.1962 CrossRefPubMed

17.

Melia J, Moss S, John L, Contributors in the participating laboratories (2004) Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 94:51–56. doi:10.1111/j.1464-4096.2004.04832.x CrossRefPubMed

18.

Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS (1998) The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control 9:519–527. doi:10.1023/A:1008805718310 CrossRefPubMed

19.

Mariotto AB, Etzioni R, Krapcho M, Feuer EJ (2007) Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer 109:1877–1886. doi:10.1002/cncr.22607 CrossRefPubMed

20.

Drummond FJ, Sharp L, Carsin A-E, Comber H (2007) Use of prostate specific antigen testing and prostatic biopsy in prostate cancer detection: a national survey of Urologists and Radiologists. UCC Annual Research Day

21.

Ito K, Yamamoto T, Suzuki K, Kurokawa K, Yamanaka H (2004) The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less. J Urol 171(2 Pt 1):656–660. doi:10.1097/01.ju.0000100109.23348.6b CrossRefPubMed

22.

Drummond FJ, Sharp L, Carsin A-E, Comber H (2007) What happens to men with an initial PSA value less than 4 ng/ml. American Association of Clinical Oncology, Florida

23.

Connolly D, Black A, Gavin A, Keane PF, Murray LJ (2008) Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomark Prev 17(2):271–278. doi:10.1158/1055-9965.EPI-07-0515 CrossRef

24.

Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J (2005) Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 165(16):1857–1861. doi:10.1001/archinte.165.16.1857 CrossRefPubMed

25.

Roobol MJ, Grenabo A, Schröder FH, Hugosson J (2007) Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst 99(17):1296–1303. doi:10.1093/jnci/djm101 CrossRefPubMed

26.

Roobol MJ, Roobol DW, Schröder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65(2):343–346. doi:10.1016/j.urology.2004.09.046 CrossRefPubMed

27.

Wilt TJ, Shamliyan T, Taylor B, MacDonald R, Tacklind J, Rutks I et al (2008) Screening for prostate cancer: U.S. Preventive Services Task Force. Ann Intern Med 149:192–199

28.

Drummond FJ, Carsin A-E, Sharp L, Comber H (2009) Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners. BMC Fam Pract 10:3. doi:10.1186/1471-2296-10-3 CrossRefPubMed

29.

Imamura T, Yasunaga H (2008) Economic evaluation of prostate cancer screening with prostate-specific antigen. Int J Urol 15:285–288. doi:10.1111/j.1442-2042.2008.02013.x CrossRefPubMed

30.

Carlsson S, Aus G, Wessman C, Hugosson J (2007) Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA)—results from a prospective, population-based, randomised study. Eur J Cancer 43(14):2109–2116. doi:10.1016/j.ejca.2007.06.002 CrossRefPubMed

31.

UK National Screening Committee Prostate Cancer Risk Management. Programme 2001. http://www.cancerscreening.nhs.uk/prostate/index.html

32.

Smith RA, Cokkinides V, Eyre HJ (2006) American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 56:11–25. doi:10.3322/canjclin.56.1.11 CrossRefPubMed

33.

American Urological Association (2000) Prostate specific antigen (PSA) best practice policy. Oncology (Williston Park) 14:267–272

34.

U.S. Preventive Services Task Force (2008) Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement 2008. Ann Intern Med 149:185–191

35.

Lawson DA, Simoes EJ, Sharp D, Murayi T, Hagan R, Brownson RC, Wilkerson J (1998) Prostate cancer screening—a physician survey in Missouri. J Community Health 23:347–358. doi:10.1023/A:1018745821888 CrossRefPubMed

36.

Moran WP, Cohen SJ, Preisser JS, Wofford JL, Shelton BJ, McClatchey MW (2000) Factors influencing use of the prostate-specific antigen screening test in primary care. Am J Manag Care 6:315–324PubMed

37.

Action prostate cancer. http://www.cancer.ie/prostate/

38.

Drummond FJ, Sharp L, Comber H (2008) PSA testing and the impact of national recommendations in general practice: a semi-qualitative study. http://www.ncri.org.uk/ncriconference/2008abstracts/abstracts/C105.htm

39.

Colditz GA, Emmons KM, Vishwanath K, Kerner JF (2008) Translating science to practice: community and academic perspectives. J Public Health Manag Pract 14:144–149PubMed

40.

Kerner JF (2008) Integrating research, practice, and policy: what we see depends on where we stand. J Public Health Manag Pract 14:193–198PubMed

41.

Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J (2008) Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol 9:445–452. doi:10.1016/S1470-2045(08)70104-9 CrossRefPubMed

42.

Carsin A-E, Drummond FJ, Black A, van Leeuwen PJ, Murray LJ, Connolly D, Egevad L, Autier P, Comber H, Gavin A. PSA testing and prostatic biopsy: population-based study of impact on cancer incidence and mortality. (under review)

43.

Brewster DH, Fraser LA, Harris V, Black RJ (2000) Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int 85:463–472. doi:10.1046/j.1464-410x.2000.00487.x CrossRefPubMed

Titel: Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines
verfasst von: F. J. Drummond
A.-E. Carsin
L. Sharp
H. Comber
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 1/2010
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-009-0376-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Prospective, controlled assessment of the impact of formal evidence-based medicine teaching workshop on ability to appraise the medical literature

An evaluation of the range and availability of intensive smoking cessation services in Ireland

The incidence of acute stroke emergency admissions in an Irish teaching hospital

A prospective randomized single blind trial of Fleet phosphate enema versus glycerin suppositories as preparation for flexible sigmoidoscopy

Douglas Argyll Robertson (1837–1909) and his pupil

Usage of herbal medications in patients undergoing IVF treatment in an Irish infertility treatment unit